Nivolumab + Relatlimab

ApprovedRecruiting

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Untreated Melanoma

Conditions

Untreated Melanoma, Unresectable Melanoma, Metastatic Melanoma

Trial Timeline

Nov 15, 2026 → May 28, 2029

NCT ID

NCT07459543

About Nivolumab + Relatlimab

Nivolumab + Relatlimab is a approved stage product being developed by Bristol Myers Squibb for Untreated Melanoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07459543. Target conditions include Untreated Melanoma, Unresectable Melanoma, Metastatic Melanoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07459543	Approved	Recruiting	Nov 15, 2026	May 28, 2029	Untreated Melanoma
NCT06237920	Phase 2	Recruiting	Feb 19, 2024	Aug 1, 2028	Urologic Neoplasms
NCT04658147	Phase 1	Active	May 28, 2021	Jun 1, 2030	Hepatocellular Carcinoma
NCT04567615	Phase 2	Completed	Feb 4, 2021	Nov 19, 2025	Hepatocellular Carcinoma
NCT04552223	Phase 2	Completed	Nov 10, 2020	Jan 4, 2026	Metastatic Uveal Melanoma
NCT03623854	Phase 2	Completed	Apr 3, 2019	Sep 28, 2023	Chordoma
NCT03610711	Phase 1/2	Active	Mar 6, 2019	Dec 1, 2026	Gastroesophageal Cancer
NCT03642067	Phase 2	Completed	Feb 12, 2019	Sep 18, 2024	Microsatellite Stable (MSS) Colorectal Adenocarcinomas

Competing Products

15 competing products in Untreated Melanoma

See all competitors

Product	Company	Stage	Hype Score
Veliparib + Placebo + Modified FOLFIRI + FOLFIRI + Bevacizumab + Fluorouracil infusion	AbbVie	Phase 2	52
Onureg + Venetoclax	AbbVie	Phase 1/2	41
Acalabrutinib + Rituximab + Chlorambucil	AstraZeneca	Phase 3	77
AZD1775 + AZD1775 Matching Placebo + pemetrexed + carboplatin	AstraZeneca	Phase 2	52
Surovatamig + R-CHOP + R-CVP + BR	AstraZeneca	Phase 3	77
MK-3475 + Lenvatinib + Carboplatin + Paclitaxel	Merck	Phase 2	52
UFOX + Cetuximab + FOLFOX4 + Cetuximab	Merck	Phase 2	52
Rituximab + Prednisone + Doxorubicine + Cyclophosphamide + Vincristine	Roche	Phase 2	52
Rituximab + ACVBP regimen plus Pegfilgrastim	Amgen	Phase 2	51
Idelalisib + Nab-paclitaxel + mFOLFOX6	Gilead Sciences	Phase 1	32
PF-08634404 + Chemotherapy + Nivolumab	Pfizer	Phase 2/3	64
Lenalidomide + Dexamethasone + Elotuzumab	Bristol Myers Squibb	Phase 3	76
Nivolumab + Albumin-bound paclitaxel + Paricalcitol + Cisplatin + Gemcitabine	Bristol Myers Squibb	Phase 2	51
Pumitamig + Folfox + Capox + Nivolumab	Bristol Myers Squibb	Phase 2/3	64
Pumitamig + FOLFOX + FOLFIRI + Bevacizumab + CAPOX	Bristol Myers Squibb	Phase 2/3	64

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved